Clinical trial Recruiting at 1 site Interventional Ages 16 and up

Using the NXSignal Device to treat ACL injuries

Official title: Efficacy of the NXSignal Device for the Treatment of Anterior Cruciate Ligament Injuries. Randomized Controlled Clinical Trial

Run by University of Las Palmas de Gran Canaria · NCT05207943 · Data updated 2026-11-12

This study is testing if the NXSignal device can help people recover better from ACL injuries after surgery compared to a placebo or standard rehab.

Quick facts

Study typeInterventional
Ages16 Years and up
SexAll
Enrollment40 (estimated)
SponsorUniversity of Las Palmas de Gran Canaria
Academic / other
Locations1 site (Las Palmas de Gran Canaria, Las Palmas)
StatusRecruiting
StartedMay 25, 2021
Main results expectedSeptember 25, 2025
Study endsDecember 25, 2025
Registry record updatedAugust 28, 2025
Trial IDNCT05207943 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals over 16 years old who have undergone ACL surgery and are mentally competent to participate.

Probably not a fit

Patients with previous knee surgeries or those with contraindications for the NXSignal device will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy of the NXSignal device in treating anterior cruciate ligament (ACL) injuries. It involves a randomized, triple-blind design where patients who have undergone ACL surgery will be divided into groups receiving either the NXSignal treatment, a placebo treatment, or standard rehabilitation. The study aims to compare outcomes among these groups to determine the effectiveness of the NXSignal device in improving recovery and preventing further joint issues. The trial will ensure that neither the patients nor the recovery specialists know which treatment is being administered to maintain objectivity.

Why it matters

Potential benefit: If successful, this treatment could provide a non-invasive alternative to surgery for ACL injuries, potentially reducing recovery time and healthcare costs.

How similar studies have gone: While the use of electrotherapy techniques in rehabilitation is common, the specific application of the NXSignal device for ACL injuries is a novel approach that has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Over 16 years old
* In normal conditions and mentally competent to participate in the study.
* Not having previous knee surgeries.
* In condition to complete the study questionnaires.

Exclusion Criteria:

* Present some of the contraindications for a treatment with NESA XSIGNAL®: pacemakers, internal bleeding, do not apply electrodes on skin in poor condition, with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and / or electricity phobia.
* Not having signed the informed consent.
* Urgent surgical interventions.

Where it's running

  • University of Las Palmas de Gran Canaria
    Las Palmas de Gran Canaria, Las Palmas, Spain
    Recruiting

Study contacts

  • Principal investigator: Aníbal Báez Suárez, PhD — University of Las Palmas de Gran Canaria
  • Study coordinator: Aníbal Báez Suárez, PhD
  • Email: anibal.baez@ulpgc.es
  • Phone: 652077692

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.